-- Scott Roberts
FRIDAY, Nov. 8 (HealthDay News) -- The first generic versions of
the anti-GERD drug Aciphex (rabeprazole sodium) have been approved
by the U.S. Food and Drug Administration for people aged 12 and
older, the agency said Friday.
Gastroesophageal reflux disease (GERD), also known as chronic
heartburn, is a very common disorder characterized by backward flow
of stomach acid to the esophagus. This process could damage tissue
in the esophagus, the tube that connects the throat and
License to produce generic rabeprazole was granted to Dr.
Reddy's Laboratories, Kremers Urban Pharmaceuticals, Lupin
Pharmaceuticals, Mylan Pharmaceuticals, Teva Pharmaceuticals and
Torrent Pharmaceuticals, the FDA said.
The drug is among a class called proton-pump inhibitors, which
are designed to reduce the amount of stomach acid produced. Generic
drugs, the FDA stressed, are equivalent to the brand-name versions
in strength and quality.
To learn more about GERD, visit
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.